Ultragenyx Pharmaceutical Q1 2024 GAAP EPS $(2.03) Misses $(1.77) Estimate, Sales $108.833M Miss $116.009M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported Q1 2024 earnings with a GAAP EPS of $(2.03), missing the $(1.77) estimate, and sales of $108.833M, below the $116.009M estimate. This represents an 8.30% increase in sales compared to the same period last year.
May 02, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ultragenyx Pharmaceutical reported lower-than-expected Q1 2024 earnings and sales, missing estimates with a GAAP EPS of $(2.03) and sales of $108.833M.
Missing both EPS and sales estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, the year-over-year sales growth might offset some negative impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100